Breast Carcinoma
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
We previously found that Aur-A activated the mTOR pathway and inhibited autophagy activity in breast cancer cell models.
|
31406104 |
2019 |
Breast Carcinoma
|
0.400 |
Biomarker
|
disease |
BEFREE |
Maintenance of AURKA after drug treatment was associated with resistance in breast cancer models.
|
29942081 |
2018 |
Breast Carcinoma
|
0.400 |
Biomarker
|
disease |
BEFREE |
Chalcones Repressed the AURKA and MDR Proteins Involved in Metastasis and Multiple Drug Resistance in Breast Cancer Cell Lines.
|
30104527 |
2018 |
Breast Carcinoma
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
Breast Cancer Risk Associated with Genotype Polymorphisms of the Aurora Kinase a Gene (AURKA): a Case-Control Study in a High Altitude Ecuadorian Mestizo Population.
|
28647900 |
2018 |
Breast Carcinoma
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
Forced expression of the mitotic Aurora kinase A (AURKA), which promotes breast cancer metastases, failed to restore the invasive capacity of NOTCH3-null cells, demonstrating that NOTCH3 expression is required for an invasive phenotype.
|
30180881 |
2018 |
Breast Carcinoma
|
0.400 |
Biomarker
|
disease |
BEFREE |
Polymer Nanovesicle-Mediated Delivery of MLN8237 Preferentially Inhibits Aurora Kinase A To Target RalA and Anchorage-Independent Growth in Breast Cancer Cells.
|
29863884 |
2018 |
Breast Carcinoma
|
0.400 |
Biomarker
|
disease |
BEFREE |
Remarkably, our data reveal a novel potential therapeutic strategy for targeting both the cytoplasmic and nuclear AURKA function to effectively eliminate BCSCs, so as to overcome both breast cancer and drug resistance.
|
28114286 |
2017 |
Breast Carcinoma
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
However, there was a significant association between tumor stages and F31I genotype (P for trend = .003).This is the first report of F31I and V57I polymorphisms in AURKA gene in breast cancer in Iran.
|
28906374 |
2017 |
Breast Carcinoma
|
0.400 |
Biomarker
|
disease |
BEFREE |
Seven candidate drug-based molecular biomarkers, human epidermal growth factor receptor (EGFR), human epidermal growth factor receptor-2 (HER2), phosphatase and tensin homolog deleted on chromosome ten (PTEN), aurora kinase A (AURKA), breast cancer susceptibility gene 1 (BRCA1), breast cancer susceptibility gene 2 (BRCA2) and programmed death-ligand 1 (PD-L1) were measured in 96 ovarian CCC and 113 HGSC by immunohistochemistry in paraffin embedded tissues.
|
28187748 |
2017 |
Breast Carcinoma
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
In addition, the variant Phe allele in STK15 rs2273535 SNP appeared to protect against breast cancer in Malaysian Chinese.
|
26925658 |
2016 |
Breast Carcinoma
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
Aurora kinase-A overexpression in mouse mammary epithelium induces mammary adenocarcinomas harboring genetic alterations shared with human breast cancer.
|
27624071 |
2016 |
Breast Carcinoma
|
0.400 |
Biomarker
|
disease |
BEFREE |
Here we show that AURKA translocates to the nucleus and causes distinct oncogenic properties in malignant cells by enhancing breast cancer stem cell (BCSC) phenotype.
|
26782714 |
2016 |
Breast Carcinoma
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
Remarkably, a strong correlation between AurkA and miR-128 expression in breast cancer tissues confirmed our findings.
|
27341528 |
2016 |
Breast Carcinoma
|
0.400 |
Biomarker
|
disease |
BEFREE |
San Huang Decoction downregulates Aurora kinase A to inhibit breast cancer cell growth and enhance chemosenstivity to anti-tumor drugs.
|
27461831 |
2016 |
Breast Carcinoma
|
0.400 |
Biomarker
|
disease |
BEFREE |
Co-delivery of hydrophobic paclitaxel and hydrophilic AURKA specific siRNA by redox-sensitive micelles for effective treatment of breast cancer.
|
25996409 |
2015 |
Breast Carcinoma
|
0.400 |
Biomarker
|
disease |
BEFREE |
Using dominant models, most AURKA SNPs demonstrated no association with breast cancer in the race-stratified analyses.
|
25328151 |
2015 |
Breast Carcinoma
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
In summary, this meta-analysis suggests that STK15 F31I polymorphism is associated with increased breast cancer and ovarian cancer risk among Caucasians, F31I polymorphism is associated with decreased lung cancer risk among Caucasians, and V57I polymorphism is associated with decreased breast cancer risk among Caucasians.
|
25154511 |
2015 |
Breast Carcinoma
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
Variation in CSTF1, located next to AURKA, was also found to be associated with breast cancer risk in BRCA2 mutation carriers: rs2426618 per-allele HR = 1.10, 95% CI 1.03-1.16, p = 0.005 (FDR-adjusted p = 0.045).
|
25830658 |
2015 |
Breast Carcinoma
|
0.400 |
Biomarker
|
disease |
BEFREE |
Our study is the first to demonstrate that Aurora kinase A and B may be treatment targets in AI-resistant cells, and our data suggest that therapy targeting both ER and Aurora kinases may be a potent treatment strategy for overcoming AI resistance in breast cancer.
|
25667100 |
2015 |
Breast Carcinoma
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
Individuals with the rs2273535 polymorphism in the AURKA gene have a higher risk of breast cancer in Asian populations, but not in Caucasians.
|
25169513 |
2014 |
Breast Carcinoma
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
Both AURKA and SURVIVIN increased expression were significantly associated with breast cancer grade.
|
25288231 |
2014 |
Breast Carcinoma
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
The present meta-analysis suggests that the STK15 F31I polymorphism is a strong predisposing risk factor for breast cancer, but no significant association existed between the STK15 V57I polymorphism and the risk of breast cancer.
|
23803310 |
2013 |
Breast Carcinoma
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
Our results indicate statistical evidence of an association between the STK15 F31I polymorphism and the increased risk of overall cancer in four genetic models: AA vs. TA+TT, AA vs. TT, AA vs. TA, and A vs. T. In a stratified analysis by cancer type, there was an increased risk of breast cancer in four genetic models: AA vs. TA+TT, AA vs. TT, AA vs. TA, and A vs. T, as well as esophageal cancer in two genetic models: AA vs. TA+TT and AA vs. TA.
|
24349361 |
2013 |
Breast Carcinoma
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
Although hypoxia is a tumor feature, the molecular mechanisms that regulate AURKA expression in response to hypoxia in BC are still unknown.
|
23925655 |
2013 |
Breast Carcinoma
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
Thirty-six publicly available breast cancer datasets (n = 5715) were subjected to molecular subtyping using five published classifiers (three SSPs and two SCMs) and SCMGENE, the new three-gene (ER, HER2, and AURKA) SCM.
|
22262870 |
2012 |